Skip to main content
PMC home page
AAPS PharmSciTech logoLink to AAPS PharmSciTech
. 2005 Sep 20;6(1):E49–E55. doi: 10.1208/pt060110

Formulation and evaluation of mucoadhesive glipizide microspheres

Jayvadan K Patel 1,✉, Rakesh P Patel 1, Avani F Amin 2, Madhabhai M Patel 1
PMCID: PMC2750411  PMID: 16353963

Abstract

The purpose of this research was to formulate and system-atically evaluate in vitro and in vivo performances of mucoadhesive microspheres of glipizide. Glipizide microspheres containing chitosan were prepared by simple emulsification phase separation technique using glutaraldehyde as a cross-linking agent. Results of preliminary trials indicate that volume of cross-linking agent, time for cross-linking, polymer-to-drug ratio, and speed of rotation affected characteristics of microspheres. Microspheres were discrete, spherical, and free flowing. The microspheres exhibited good mucoadhesive property in the in vitro wash-off test and also showed a high percentage drug entrapment efficiency. A 32 full factorial design was employed to study the effect of independent variables, polymer-to-drug ratio (X1), and stirring speed (X2) on dependent variables percentage mucoadhesion, t80, drug entrapment efficiency, and swelling index. The best batch exhibited a high drug entrapment efficiency of 75% and a swelling index of 1.42; percentage mucoadhesion after 1 hour was 78%. The drug release was also sustained for more than 12 hours. The polymer-to-drug ratio had a more significant effect on the dependent variables. In vivo testing of the mucoadhesive microspheres to albino Wistar rats demonstrated significant hypoglycemic effect of glipizide.

Keywords: chitosan, mucoadhesive microspheres, glipizide, factorial design, in vivo study

Full Text

The Full Text of this article is available as a PDF (217.8 KB).

References

  • 1.Woo BH, Jiang G, Jo YW, DeLuca PP. Preparation and characterization of a composite PLGA and poly (acryloyl hydroxymethyl starch) microsphere system for protein delivery. Pharm Res. 2001;18:1600–1606. doi: 10.1023/A:1013090700443. [DOI] [PubMed] [Google Scholar]
  • 2.Capan Y, Jiang G, Giovagnoli S, DeLuca PP. Preparation and characterization of poly (D,L-lactide-co-glycolide) microsphere for controlled release of human growth hormone. AAPS PharmSciTech. 2003;4:E28–E28. doi: 10.1208/pt040228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Gohel MC, Amin AF. Formulation optimization of controlled release diclofenac sodium microspheres using factorial design. J Control Release. 1998;51:115–122. doi: 10.1016/S0168-3659(97)00102-8. [DOI] [PubMed] [Google Scholar]
  • 4.Vasir JK, Tambwekar K, Garg S. Bioadhesive microspheres as a controlled drug delivery system. Int J Pharm. 2003;255:13–32. doi: 10.1016/S0378-5173(03)00087-5. [DOI] [PubMed] [Google Scholar]
  • 5.Ikeda K, Murata K, Kobayashi M, Noda K. Enhancement of bioavailability of dopamine via nasal route in beagle dogs. Chem Pharm Bull (Tokyo) 1992;40:2155–2158. doi: 10.1248/cpb.40.2155. [DOI] [PubMed] [Google Scholar]
  • 6.Nagai T, Nishimoto Y, Nambu N, Suzuki Y, Sekine K. Powder dosage form of insulin for nasal administration. J Control Release. 1984;1:15–22. doi: 10.1016/0168-3659(84)90017-8. [DOI] [Google Scholar]
  • 7.Ilium L, Farraj NF, Critchley H, Davis SS. Nasal administration of gentamicin using a novel microsphere delivery system. Int J Pharm. 1988;46:261–265. doi: 10.1016/0378-5173(88)90087-7. [DOI] [Google Scholar]
  • 8.Schaefer MJ, Singh J. Effect of isopropyl myristic acid ester on the physical characteristics and in vitro release of etoposide from PLGA microspheres. AAPS PharmSciTech. 2000;1:E32–E32. doi: 10.1208/pt010432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Rao SB, Sharma CP. Use of chitosan as biomaterial: studies on its safety and hemostatic potential. J Biomed Mater Res. 1997;34:21–28. doi: 10.1002/(SICI)1097-4636(199701)34:1<21::AID-JBM4>3.0.CO;2-P. [DOI] [PubMed] [Google Scholar]
  • 10.Lehr CM, Bouwstra JA, Schacht EH, Junginger HE. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int J Pharm. 1992;78:43–48. doi: 10.1016/0378-5173(92)90353-4. [DOI] [Google Scholar]
  • 11.Henriksen I, Green KL, Smart JD, Smistad G, Karlsen J. Bioadhesion of hydrated chitosans: an in vitro and in vivo study. Int J Pharm. 1996;145:231–240. doi: 10.1016/S0378-5173(96)04776-X. [DOI] [Google Scholar]
  • 12.Chowdary KPR, Rao YS. Design and in vitro and in vivo evaluation of mucoadhesive microcapsules of glipizide for oral controlled release: a technical note. AAPS PharmSciTech. 2003;4:E39–E39. doi: 10.1208/pt040339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Thanoo BC, Sunny MC, Jayakrishnan A. Cross-linked chitosan microspheres: preparation and evaluation as a matrix for the controlled release of pharmaceuticals. J Pharm Pharmacol. 1992;44:283–286. doi: 10.1111/j.2042-7158.1992.tb03607.x. [DOI] [PubMed] [Google Scholar]
  • 14.Hari PR, Chandy T, Sharma CP. Chitosan/calcium alginate microcapsules for intestinal delivery of nitrofurantoin. J Microencapsul. 1996;13:319–329. doi: 10.3109/02652049609026019. [DOI] [PubMed] [Google Scholar]
  • 15.Liu LS, Liu SQ, Ng SY, Froix M, Heller J. Controlled release of interleukin 2 for tumour immunotherapy using alginate/chitosan porous microspheres. J Control Release. 1997;43:65–74. doi: 10.1016/S0168-3659(96)01471-X. [DOI] [Google Scholar]
  • 16.Patel JK, Bodar MS, Amin AF, Patel MM. Formulation and optimization of mucoadhesive microspheres of metoclopramide. Ind J Pharm Sci. 2004;66:300–305. [Google Scholar]
  • 17.Dubey RR, Parikh RH. Two-stage optimization process for formulation of chitosan microspheres. AAPS PharmSciTech. 2004;5:E5–E5. doi: 10.1208/pt050105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Foster RH, Plosker GL. Glipizide: a review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus. Pharmacoeconomics. 2000;18:289–306. doi: 10.2165/00019053-200018030-00008. [DOI] [PubMed] [Google Scholar]
  • 19.Thombre AG, Denoto AR, Gibbes DC. Delivery of glipizide from asymmetric membrane capsules using encapsulated excipients. J Control Release. 1999;60:333–341. doi: 10.1016/S0168-3659(99)00086-3. [DOI] [PubMed] [Google Scholar]
  • 20.Chowdary KPR, Balatripura G. Design and in vitro evaluation of mucoadhesive controlled release oral tablets of glipizide. Ind J Pharm Sci. 2003;65:591–594. [Google Scholar]
  • 21.The United States Pharmacopeia. Rockville, MD: The United States Pharmacopeial Convention, Inc; 2003. pp. 859–859. [Google Scholar]
  • 22.Eugene L. Milling. In: Lachman L, Liberman HA, editors. The Theory and Practice of Industrial Pharmacy. 2nd ed. Mumbai, India: Varghese Publishing House; 1991. pp. 26–27. [Google Scholar]
  • 23.The United States Pharmacopeia. Rockville, MD: The United States Pharmacopeial Convention, Inc; 2003. pp. 2528–2528. [Google Scholar]
  • 24.El-Gibaly I. Development and in vitro evaluation of novel floating chitosan microcapsules for oral use: comparison with non-floating chitosan microspheres. Int J Pharm. 2002;249:7–21. doi: 10.1016/S0378-5173(02)00396-4. [DOI] [PubMed] [Google Scholar]
  • 25.Lehr CM, Bowstra JA, Tukker JJ, Junginger HE. Intestinal transit of bioadhesive microspheres in an in situ loop in the rat. J Control Release. 1990;13:51–62. doi: 10.1016/0168-3659(90)90074-4. [DOI] [Google Scholar]
  • 26.Nelson KG, Wang LY. Determination of time course of tablet disintegration II: method using continuous functions. J Pharm Sci. 1961;67:86–89. doi: 10.1002/jps.2600670122. [DOI] [PubMed] [Google Scholar]
  • 27.Lee JW, Park JH, Robinson JR. Bioadhesive-based dosage forms: the next generation. J Pharm Sci. 2000;89:850–866. doi: 10.1002/1520-6017(200007)89:7<850::AID-JPS2>3.0.CO;2-G. [DOI] [PubMed] [Google Scholar]
  • 28.Bamba M, Puisieux F, Marty JP, Carstensen JT. Release mechanisms in gelforming sustained release preparations. Int J Pharm. 1979;2:307–315. doi: 10.1016/0378-5173(79)90037-1. [DOI] [Google Scholar]
  • 29.Kahn CR, Shechter Y. Oral hypoglycemic agents and the pharmacology of the endocrine pancreas. In: Theodore WR, Alan SN, Taylor P, Gilman AG, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY: McGraw-Hill; 1991. pp. 1461–1495. [Google Scholar]
  • 30.Berelowitz M, Fischette C, Cefelu W, Schade DS, Sutfin T, Kourides IA. Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM. Diabetes Care. 1994;17:1460–1464. doi: 10.2337/diacare.17.12.1460. [DOI] [PubMed] [Google Scholar]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES